

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2024 July 14; 30(26): 3185-3263



**EDITORIAL**

- 3185 Device-assisted enteroscopy: Are we ready to dismiss the spiral?  
*Mussetto A, Merola E, Casadei C, Salvi D, Fornaroli F, Cocca S, Trebbi M, Gabbrielli A, Spada C, Michielan A*
- 3193 Reactivation of hepatitis B virus infection – an important aspect of multifaceted problem  
*Morozov S, Batskikh S*
- 3198 Non-participation of asymptomatic candidates in screening protocols reduces early diagnosis and worsens prognosis of colorectal cancer  
*Pérez-Holanda S*
- 3201 Digesting gluten with oral endopeptidases to improve the management of celiac disease  
*Durham K, Ince MN*
- 3206 Tumor-related factor complement C1q/TNF-related protein 6 affects the development of digestive system tumors through the phosphatidylinositol 3-kinase pathway  
*Kong MW, Li XR, Gao Y, Yang TF*

**ORIGINAL ARTICLE****Retrospective Cohort Study**

- 3210 Yield of alarm features in predicting significant endoscopic findings among hospitalized patients with dyspepsia  
*Ibrahim L, Basheer M, Houry T, Sbeit W*

**Retrospective Study**

- 3221 Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study  
*Ghazanfar H, Javed N, Qasim A, Sosa F, Altaf F, Khan S, Mahasamudram J, Jyala A, Kandhi SD, Shin D, Mantri N, Sun H, Hanumanthu S, Patel H, Makker J, Balar B, Dev A, Chilimuri S*

**Basic Study**

- 3229 Loss of monopolar spindle-binding protein 3B expression promotes colorectal cancer malignant behaviors by activation of target of rapamycin kinase/autophagy signaling  
*Sun J, Zhang JX, Li MS, Qin MB, Cheng RX, Wu QR, Chen QL, Yang D, Liao C, Liu SQ, Huang JA*

**CASE REPORT**

- 3247 Early detection of multiple endocrine neoplasia type 1: A case report  
*Yuan JH, Luo S, Zhang DG, Wang LS*

**LETTER TO THE EDITOR**

- 3253** Mean nocturnal baseline impedance in gastro-esophageal reflux disease diagnosis: Should we strictly follow the Lyon 2 Consensus?  
*Voulgaris TA, Karamanolis GP*
- 3257** Photo-activated microtubule targeting drugs: Advancing therapies for colorectal cancer  
*Singh N, Sharma S*
- 3261** Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients  
*Meng LY, Yang CT, Bao JF, Huang JS*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastroenterology*, Zhao-Shan Niu, MD, Associate Professor, Laboratory of Micromorphology, School of Basic Medicine, Qingdao Medical College of Qingdao University, Qingdao 266071, Shandong Province, China. z.s.niu@qdu.edu.cn

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastroenterology* (*WJG*, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. *WJG* mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

**INDEXING/ABSTRACTING**

The *WJG* is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for *WJG* as 4.3; Quartile: Q1. The *WJG*'s CiteScore for 2023 is 7.8.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Ying-Yi Yuan*; Production Department Director: *Xiang Li*; Cover Editor: *Jia-Ru Fan*.

**NAME OF JOURNAL**

*World Journal of Gastroenterology*

**ISSN**

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

**LAUNCH DATE**

October 1, 1995

**FREQUENCY**

Weekly

**EDITORS-IN-CHIEF**

Andrzej S Tarnawski

**EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF**

Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu

**EDITORIAL BOARD MEMBERS**

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

**PUBLICATION DATE**

July 14, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**PUBLISHING PARTNER**

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University  
Biliary Tract Disease Institute, Fudan University

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**POLICY OF CO-AUTHORS**

<https://www.wjgnet.com/bpg/GerInfo/310>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

**PUBLISHING PARTNER'S OFFICIAL WEBSITE**

<https://www.shca.org.cn>  
<https://www.zs-hospital.sh.cn>

## Photo-activated microtubule targeting drugs: Advancing therapies for colorectal cancer

Naresh Singh, Samantha Sharma

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's classification**

**Scientific Quality:** Grade B

**Novelty:** Grade B

**Creativity or Innovation:** Grade B

**Scientific Significance:** Grade B

**P-Reviewer:** Fu Z

**Received:** April 16, 2024

**Revised:** June 11, 2024

**Accepted:** June 24, 2024

**Published online:** July 14, 2024

**Processing time:** 84 Days and 10.1 Hours



**Naresh Singh, Samantha Sharma**, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, United States

**Corresponding author:** Samantha Sharma, PhD, Research Scientist, Department of Medical and Molecular Genetics, Indiana University School of Medicine, 980 W Walnut Street, R3.C260, Indianapolis, IN 46202, United States. [samshar@iu.edu](mailto:samshar@iu.edu)

### Abstract

Over the years immunotherapy has demonstrably improved the field of cancer treatment. However, achieving long-term survival for colorectal cancer (CRC) patients remains a significant unmet need. Combination immunotherapies incorporating targeted drugs like MEK or multi-kinase inhibitors have offered some palliative benefit. Nevertheless, substantial gaps remain in the current therapeutic armamentarium for CRC. In recent years, there has been a surge of interest in exploring novel treatment strategies, including the application of light-activated drugs in conjunction with optical devices. This approach holds promise for achieving localized and targeted delivery of cytotoxic agents, such as microtubule-targeting drugs, directly to cancerous cells within the colon.

**Key Words:** Colorectal cancer; Therapy; Microtubule; Photo pharmacology; Immunotherapies

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** While progress has been made in colorectal cancer (CRC) treatment, significant challenges remain, as highlighted by the persistently low five-year survival rate. Integrating chemotherapy with other targeted therapies has shown promise, particularly in immune cold microsatellite stable or mutation-related CRCs. The emergence of personalized medicine, leveraging photo-switchable microtubule (MT)-targeted drugs, represents a novel approach in CRC management. While traditional MT-targeted drugs like taxanes have shown limited efficacy in CRC, optically controlled MT-drugs hold potential for improving treatment outcomes in CRC patients.

**Citation:** Singh N, Sharma S. Photo-activated microtubule targeting drugs: Advancing therapies for colorectal cancer. *World J Gastroenterol* 2024; 30(26): 3257-3260

**URL:** <https://www.wjgnet.com/1007-9327/full/v30/i26/3257.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v30.i26.3257>

## TO THE EDITOR

Could light be the key to better colorectal cancer (CRC) treatment? The recent review by Kita *et al*[1], titled “Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management” is particularly timely and clinically relevant article offering the potential of optical control for more effective CRC treatment. The review is aimed towards improving treatment of CRC patients with a focus on therapeutic potential of microtubule (MT)-inhibitor drugs. The review provides new insights in using combination therapy of optical devices and photo-activable drug allowing to locally target advanced stage of CRC cells.

Over the years, significant advancements have been made in the field of CRC therapeutics, resulting in improved survival rates attributed to progress in both primary and adjuvant treatment methods[2]. Notably, the integration of chemotherapy as either a neoadjuvant or adjuvant intervention has emerged as a strategic approach to mitigating tumor burden, reducing its size, and stabilizing its growth[3]. Chemotherapy retains its central role in current treatment protocols of CRC tumors[4]. However, its effectiveness is hindered by a narrow therapeutic window, notable adverse effects, and the frequent development of acquired resistance. Additionally, various chemotherapy agents, radiotherapies, and other physical interventions also induce cellular and tissue destruction, releasing immunogenic signals that paradoxically activate the immune system[5]. This phenomenon highlights the complex interplay between treatment modalities and the tumor microenvironment. However, currently few combinations of chemotherapy regimens have been used in the treatment of CRC patients. This includes the use of bevacizumab and fruquintinib representing a humanized anti-vascular endothelial growth factor-A antibody and vascular endothelial growth factor receptor tyrosine kinase inhibitor, respectively[6,7]. These interventions lead to a significant decrease in disease progression. Although these interventions also cause an increase in treatment related adverse effects.

Immune checkpoint inhibitors (ICIs) have demonstrated encouraging clinical results in treating CRC by blocking proteins that regulate immune responses[8]. ICIs exhibit superior efficacy in microsatellite instability-high/mismatch repair-deficient tumors due to their ability to enhance tumor neoantigen presentation, leading to potent immune recognition and elimination of cancer cells. These therapies demonstrate efficacy; however, inherent tumor heterogeneity, as exemplified by microsatellite stable/mismatch repair-proficient CRC, limits patient response, necessitating tailored treatment strategies[9]. MT-targeted drugs, a chemotherapy drug disrupt the cytoskeletal network vital for cell division, impeding tumor proliferation[10]. While demonstrating efficacy, their effectiveness varies among patients, prompting ongoing research to refine treatment protocols. This challenge is compounded by the intrinsic or acquired resistance of CRC tumors to a broad spectrum of chemotherapeutics, potentially due to high P-glycoprotein expression[11]. While numerous MT-targeted have shown success in cancers like breast, ovarian, and lung, current CRC clinical trials primarily focus on paclitaxel and its derivatives[12]. Nevertheless, these MT-targeting drugs did not provide much improved overall survival in CRC patients.

In CRC treatment, traditional natural compound-based drugs have demonstrated effectiveness, with recent advancements utilizing biosynthetic bioengineering techniques to refine these agents. For instance, combretastatin A-4 (CA-4) and its analogs have undergone extensive synthesis and evaluation[13]. Among these, isoCA-4 has shown promise due to its stability and similar efficacy to CA-4[14]. However, the trans-isomer of CA-4, which is less efficient in inhibiting CRC cell growth and prone to isomerization during storage and metabolism, poses a challenge due to its heightened toxicity [15]. Nonetheless, if local conformational modulation can be achieved, CA-4 or its analogs hold potential as potent anti-cancer chemotherapy agents. CA-4 acts by destabilizing MTs and exhibiting anti-angiogenic effects, like the mechanism of action of paclitaxel and navicixizumab.

Photoactivation emerges as a promising strategy for localized activation of CA-4, enabling targeted control over drug release within tumors. The first photoactivated CA-4, dithiaporphyrin-aminoacylate-CA-4, introduced in 2013, efficiently liberates CA-4 upon irradiation with a 690 nm laser (over 80% release within 10 minutes)[16]. However, this approach comes with a trade-off, as it exhibits a 6-fold increase in the half-maximal inhibitory concentration, potentially indicating reduced potency. In 2015, photo switchable photostatins (PSTs) were developed, replacing the C=C double bond with an N=N double bond, leading to more efficient photoactivation[17]. The most promising variant demonstrates a 101-fold activation upon photo-isomerization. While PSTs do undergo spontaneous cis-to-trans isomerization, rapid conversion back to the active cis-form can be achieved using short light pulses. Additionally, PSTs demonstrated stability with over 5000 switches over two days, offering a potentially promising, photoactivatable CA-4. Alongside CA-4, other MT-targeted drugs were developed as photo switchable derivatives, namely paclitaxel and docetaxel[18]. However, these faced challenges such as toxicity and low solubility, respectively. Novel photo-switchable compounds have emerged from established MT-targeting medications. Nevertheless, their potency shift dynamic range currently does not match that observed in combretastatin analogs, which may range from 60 to 100 folds. Advancements in optical fiber technologies have facilitated the directed delivery of two-photon excitation beams into tissues, extending the application of two-photon excitation to colon cells[19]. This progress led to the development of the first clinical two-photon endoscope in the same year. However, to date, there have been no reports on attempts to photo-activate CA-4 analogs *in vivo*. Further exploration of CA-4-based photo pharmacology is anticipated.

In conclusion, the merger of light and medicine ignites a revolutionary approach to CRC therapy. Emerging optical control strategies for MT-targeting drugs unlock a new paradigm in CRC management, offering unprecedented potential to overcome limitations associated with conventional options. This exciting avenue complements the promise of ICIs, each strategy pushing the boundaries of personalized CRC treatment. While challenges remain, advancements in optical fiber technologies have expanded the application of two-photon excitation and further exploration of photo-pharmacology, particularly with CA-4 analogs, holds promise for advancing CRC treatment.

## FOOTNOTES

**Author contributions:** Singh N and Sharma S conceived the idea and wrote the manuscript; Singh N and Sharma S contributed equally to the manuscript.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country of origin:** United States

**ORCID number:** Naresh Singh [0000-0003-4051-4084](https://orcid.org/0000-0003-4051-4084); Samantha Sharma [0000-0001-9599-4455](https://orcid.org/0000-0001-9599-4455).

**S-Editor:** Wang JJ

**L-Editor:** A

**P-Editor:** Yuan YY

## REFERENCES

- 1 **Kita K**, Burdowski A. Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management. *World J Gastroenterol* 2024; **30**: 1780-1790 [PMID: [38659489](https://pubmed.ncbi.nlm.nih.gov/38659489/) DOI: [10.3748/wjg.v30.i13.1780](https://doi.org/10.3748/wjg.v30.i13.1780)]
- 2 **Sharma S**, Singh N, Turk AA, Wan I, Guttikonda A, Dong JL, Zhang X, Opyrchal M. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions. *World J Gastroenterol* 2024; **30**: 1815-1835 [PMID: [38659481](https://pubmed.ncbi.nlm.nih.gov/38659481/) DOI: [10.3748/wjg.v30.i13.1815](https://doi.org/10.3748/wjg.v30.i13.1815)]
- 3 **Van Cutsem E**, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; **25** Suppl 3: iii1-iii9 [PMID: [25190710](https://pubmed.ncbi.nlm.nih.gov/25190710/) DOI: [10.1093/annonc/mdu260](https://doi.org/10.1093/annonc/mdu260)]
- 4 **Schirmacher V**. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). *Int J Oncol* 2019; **54**: 407-419 [PMID: [30570109](https://pubmed.ncbi.nlm.nih.gov/30570109/) DOI: [10.3892/ijo.2018.4661](https://doi.org/10.3892/ijo.2018.4661)]
- 5 **Rodriguez-Ruiz ME**, Vitale I, Harrington KJ, Melero I, Galluzzi L. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. *Nat Immunol* 2020; **21**: 120-134 [PMID: [31873291](https://pubmed.ncbi.nlm.nih.gov/31873291/) DOI: [10.1038/s41590-019-0561-4](https://doi.org/10.1038/s41590-019-0561-4)]
- 6 **Dasari A**, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, Garcia-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csösz T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Taberero J, Eng C; FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. *Lancet* 2023; **402**: 41-53 [PMID: [37331369](https://pubmed.ncbi.nlm.nih.gov/37331369/) DOI: [10.1016/S0140-6736\(23\)00772-9](https://doi.org/10.1016/S0140-6736(23)00772-9)]
- 7 **Prager GW**, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Pápai Z, Poureau PG, Liposits G, Cremolini C, Bondarenko I, Modest DP, Benhadji KA, Amellal N, Leger C, Vidot L, Taberero J; SUNLIGHT Investigators. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. *N Engl J Med* 2023; **388**: 1657-1667 [PMID: [37133585](https://pubmed.ncbi.nlm.nih.gov/37133585/) DOI: [10.1056/NEJMoa2214963](https://doi.org/10.1056/NEJMoa2214963)]
- 8 **Chen X**, Chen LJ, Peng XF, Deng L, Wang Y, Li JJ, Guo DL, Niu XH. Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations. *Transl Oncol* 2024; **40**: 101851 [PMID: [38042137](https://pubmed.ncbi.nlm.nih.gov/38042137/) DOI: [10.1016/j.tranon.2023.101851](https://doi.org/10.1016/j.tranon.2023.101851)]
- 9 **Bai J**, Chen H, Bai X. Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment. *J Clin Lab Anal* 2021; **35**: e23810 [PMID: [33938589](https://pubmed.ncbi.nlm.nih.gov/33938589/) DOI: [10.1002/jcla.23810](https://doi.org/10.1002/jcla.23810)]
- 10 **Lafanechère L**. The microtubule cytoskeleton: An old validated target for novel therapeutic drugs. *Front Pharmacol* 2022; **13**: 969183 [PMID: [36188585](https://pubmed.ncbi.nlm.nih.gov/36188585/) DOI: [10.3389/fphar.2022.969183](https://doi.org/10.3389/fphar.2022.969183)]
- 11 **Ashique S**, Bhowmick M, Pal R, Khatoon H, Kumar P, Sharma H, Garg A, Kumar S, Das U. Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success. *Adv Cancer Biol Metastas* 2024; **10**: 100114 [DOI: [10.1016/j.adcanc.2024.100114](https://doi.org/10.1016/j.adcanc.2024.100114)]
- 12 **Yardley DA**. nab-Paclitaxel mechanisms of action and delivery. *J Control Release* 2013; **170**: 365-372 [PMID: [23770008](https://pubmed.ncbi.nlm.nih.gov/23770008/) DOI: [10.1016/j.jconrel.2013.05.041](https://doi.org/10.1016/j.jconrel.2013.05.041)]
- 13 **Messaoudi S**, Tréguier B, Hamze A, Provot O, Peyrat JF, De Losada JR, Liu JM, Bignon J, Wdzieczak-Bakala J, Thoret S, Dubois J, Brion JD, Alami M. Isocombretastatins a versus combretastatins a: the forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent. *J Med Chem* 2009; **52**: 4538-4542 [PMID: [19530698](https://pubmed.ncbi.nlm.nih.gov/19530698/) DOI: [10.1021/jm900321u](https://doi.org/10.1021/jm900321u)]
- 14 **Hamze A**, Giraud A, Messaoudi S, Provot O, Peyrat JF, Bignon J, Liu JM, Wdzieczak-Bakala J, Thoret S, Dubois J, Brion JD, Alami M.

- Synthesis, biological evaluation of 1,1-diarylethylenes as a novel class of antimetabolic agents. *ChemMedChem* 2009; **4**: 1912-1924 [PMID: 19790205 DOI: 10.1002/cmdc.200900290]
- 15 **McLoughlin EC**, O'Boyle NM. Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review. *Pharmaceuticals (Basel)* 2020; **13** [PMID: 31947889 DOI: 10.3390/ph13010008]
- 16 **Bio M**, Rajaputra P, Nkepan G, Awuah SG, Hossion AM, You Y. Site-specific and far-red-light-activatable prodrug of combretastatin A-4 using photo-unclick chemistry. *J Med Chem* 2013; **56**: 3936-3942 [PMID: 23631389 DOI: 10.1021/jm400139w]
- 17 **Borowiak M**, Nahaboo W, Reynders M, Nekolla K, Jalinot P, Hasserodt J, Rehberg M, Delattre M, Zahler S, Vollmar A, Trauner D, Thorn-Seshold O. Photoswitchable Inhibitors of Microtubule Dynamics Optically Control Mitosis and Cell Death. *Cell* 2015; **162**: 403-411 [PMID: 26165941 DOI: 10.1016/j.cell.2015.06.049]
- 18 **Dcona MM**, Mitra K, Hartman MCT. Photocontrolled activation of small molecule cancer therapeutics. *RSC Med Chem* 2020; **11**: 982-1002 [PMID: 33479692 DOI: 10.1039/d0md00107d]
- 19 **Lelek M**, Suran E, Louradour F, Barthelemy A, Viellerobe B, Lacombe F. Coherent femtosecond pulse shaping for the optimization of a non-linear micro-endoscope. *Opt Express* 2007; **15**: 10154-10162 [PMID: 19547364 DOI: 10.1364/oe.15.010154]





Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

